Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTUNG.L Regulatory News (TUNG)

  • There is currently no data for TUNG

Market update

25 Sep 2014 07:27

RNS Number : 5777S
Tungsten Corporation PLC
25 September 2014
 

TUNGSTEN CORPORATION PLC 

 

("Tungsten" or the "Company")

 

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, IN, INTO OR FROM THE UNITED STATES, CANADA, AUSTRALIA, JAPAN NOR ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION

 

 

For Immediate Release 25 September 2014

 

 

Market update

Pharmaceutical and healthcare companies continue to choose Tungsten Network

Seven of the top-twelve global pharmaceutical businesses use the global e-Invoicing network

 

London, 25 September - Tungsten Network is the e-Invoicing provider of choice for the world's leading pharmaceutical and healthcare companies.

The latest organisations to select Tungsten Network include Fresenius Medical Care NA, a US-based provider of kidney dialysis services and renal care products, and Dana-Farber Cancer Institute, a world leader in cancer treatment and research.

These new customers join the global e-Invoicing network alongside long-term practitioners, such as GlaxoSmithKline, and reinforce Tungsten's strength in this industry. Seven of the twelve largest pharmaceutical companies in the world, ranked by revenue, transact with their suppliers through Tungsten Network.

"The pharmaceutical sector has been an early adopter of e-Invoicing with our first customer from the industry joining the network in 2004," says Edmund Truell, Tungsten Group CEO. "It's befitting that an industry focused on innovation is equally pioneering in its own business practices."

 

Enquiries:

 

Tungsten Corporation plc

Edmund Truell, Chief Executive Officer +44 20 3435 5680

 

Charles Stanley Securities

(Nominated Adviser and Joint Broker)

Marc Milmo/Dugald Carlean +44 20 7149 6000

 

Canaccord Genuity Limited

(Joint Broker)

Simon Bridges/Peter Stewart/Cameron Duncan +44 20 7523 8000

 

Equus Group (Communications)

Piers Hooper / Sam Barton +44 20 7223 1100

 

About Tungsten Corporation plcTungsten Corporation (LSE: TUNG) accelerates global trade by enabling customers to streamline invoice processing, improve cash-flow management and make better buying decisions from their detailed spend data.

 

Buyer organisations that join Tungsten Network, built on OB10 e-Invoicing, can reduce their invoice-processing costs by 60%. Suppliers benefit from efficiencies, greater visibility of their invoice status and peace of mind. Tungsten offers supply chain financing through Tungsten Bank and helps buying organisations profit by applying real-time spend analytics to its vast repository of line-level invoice data.

 

Tungsten serves 53% of the Fortune 500 and 66% of the FTSE 100 by connecting the world's largest companies and government agencies to their thousands of suppliers around the globe. It is compliant in 46 countries, and last year processed transactions worth over $187bn for organisations such as Alliance Data, Aviva, Cargill, Deutsche Lufthansa, General Motors, GlaxoSmithKline, Henkel, IBM, Kellogg's, and US Federal Government.

 

Tungsten Corporation joined forces with OB10 in 2013 to create the world's largest electronic trading network.

 

Contact: Sandra Higgison, Head of Global Communications, +44 20 7280 7973, sandra.higgison@tungsten-network.com.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NRALAMFTMBBTMLI
Date   Source Headline
19th Sep 20166:13 pmRNSGrant of Share Options
16th Sep 20164:08 pmRNSResult of AGM
16th Sep 20167:00 amRNSAGM Statement & Trading Update
15th Aug 201611:38 amRNSHolding(s) in Company
5th Aug 201612:38 pmRNSMailing of Annual Report, AGM Notice & Proxy Form
28th Jul 20169:26 amRNSDirector/PDMR Shareholding
28th Jul 20167:00 amRNSHolding(s) in Company - Disruptive Capital Invts
27th Jul 201612:00 pmRNSGrant of Share Options
26th Jul 20167:07 amRNSDirector/PDMR Shareholding - Nick Parker
25th Jul 201611:40 amRNSHolding(s) in Company
25th Jul 20167:00 amRNSFinal Results
11th Jul 20167:00 amRNSHolding(s) in Company
8th Jul 20164:40 pmRNSSecond Price Monitoring Extn
8th Jul 20164:35 pmRNSPrice Monitoring Extension
24th May 20167:00 amRNSPre-Close Trading Update
11th May 20164:37 pmRNSNotice of Pre-Close Trading Update and FY Results
18th Apr 20164:40 pmRNSSecond Price Monitoring Extn
18th Apr 20164:35 pmRNSPrice Monitoring Extension
7th Apr 201610:47 amRNSHolding(s) in Company
6th Apr 20163:45 pmRNSHolding(s) in Company
4th Apr 20163:13 pmRNSHolding(s) in Company
4th Apr 20167:00 amRNSHolding(s) in Company
21st Mar 20167:01 amRNSResponse to Press Speculation
21st Mar 20167:00 amRNSDirectorate Change
18th Mar 20168:22 amRNSHolding(s) in Company
10th Mar 20167:00 amRNSDeferred Consideration
3rd Mar 20163:49 pmRNSHolding(s) in Company
18th Feb 20162:24 pmRNSDirector/PDMR Shareholding
17th Feb 20165:10 pmRNSDirector/PDMR Shareholding
9th Feb 20167:00 amRNSCapital Markets Day and Trading Update
1st Feb 20165:20 pmRNSTotal Voting Rights
21st Jan 201612:29 pmRNSHolding(s) in Company
20th Jan 20163:58 pmRNSHolding(s) in Company
19th Jan 20168:27 amRNSHolding(s) in Company
19th Jan 20168:23 amRNSHolding(s) in Company
19th Jan 20168:22 amRNSHolding(s) in Company
19th Jan 20168:17 amRNSHolding(s) in Company
15th Jan 20163:50 pmRNSHolding(s) in Company
13th Jan 20168:28 amRNSDirector/PDMR Shareholding
11th Jan 20163:27 pmRNSHolding(s) in Company
7th Jan 20163:21 pmRNSDirector Shareholding and Issue of Equity
29th Dec 20157:59 amRNSHolding(s) in Company
29th Dec 20157:57 amRNSHolding(s) in Company
23rd Dec 201510:56 amRNSHolding(s) in Company
16th Dec 201512:18 pmRNSHolding(s) in Company
16th Dec 20158:40 amRNSAgreement Reached for Sale of Tungsten Bank
16th Dec 20158:00 amRNSHalf Yearly Report
15th Dec 20154:35 pmRNSPrice Monitoring Extension
9th Dec 201511:42 amRNSHolding(s) in Company
9th Dec 201511:40 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.